Benign multiple sclerosis: A distinct clinical entity with therapeutic implications

Sean J Pittock, M. Rodriguez

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available diseasemodifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.

Original languageEnglish (US)
Pages (from-to)1-17
Number of pages17
JournalCurrent Topics in Microbiology and Immunology
Volume318
DOIs
StatePublished - 2008

Fingerprint

Multiple Sclerosis
Evidence-Based Medicine
Population
Cohort Studies
Therapeutics
Cross-Sectional Studies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology
  • Immunology and Microbiology(all)

Cite this

Benign multiple sclerosis : A distinct clinical entity with therapeutic implications. / Pittock, Sean J; Rodriguez, M.

In: Current Topics in Microbiology and Immunology, Vol. 318, 2008, p. 1-17.

Research output: Contribution to journalArticle

@article{2e4f2e37c6b6493d98edbab4cff9e0d5,
title = "Benign multiple sclerosis: A distinct clinical entity with therapeutic implications",
abstract = "This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available diseasemodifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.",
author = "Pittock, {Sean J} and M. Rodriguez",
year = "2008",
doi = "10.1007/978-3-540-73677-6-1",
language = "English (US)",
volume = "318",
pages = "1--17",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Benign multiple sclerosis

T2 - A distinct clinical entity with therapeutic implications

AU - Pittock, Sean J

AU - Rodriguez, M.

PY - 2008

Y1 - 2008

N2 - This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available diseasemodifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.

AB - This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available diseasemodifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.

UR - http://www.scopus.com/inward/record.url?scp=39549107778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549107778&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-73677-6-1

DO - 10.1007/978-3-540-73677-6-1

M3 - Article

C2 - 18219812

AN - SCOPUS:39549107778

VL - 318

SP - 1

EP - 17

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

ER -